Receptors, Purinergic P2Y12
"Receptors, Purinergic P2Y12" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A subclass of purinergic P2Y receptors that have a preference for ADP binding and are coupled to GTP-BINDING PROTEIN ALPHA SUBUNIT, GI. The P2Y12 purinergic receptors are found in PLATELETS where they play an important role regulating PLATELET ACTIVATION.
| Descriptor ID |
D058925
|
| MeSH Number(s) |
D12.776.543.750.695.700.720.500.300 D12.776.543.750.720.700.720.750.300
|
| Concept/Terms |
Receptors, Purinergic P2Y12- Receptors, Purinergic P2Y12
- P2Y12 Receptors, Purinergic
- Purinergic P2Y12 Receptors
- Purinergic Receptor P2Y, G-Protein Coupled, 12
- Purinoceptor P2Y12
- P2Y12, Purinoceptor
- P2Y12 Purinoceptors
- Purinoceptors, P2Y12
- P2Y(ADP) Receptor
- P2Y(T) Receptor
- P2Y12 Purinoceptor
- Purinoceptor, P2Y12
- Purinoceptor P2T
- P2T, Purinoceptor
- Purinergic Receptor P2Y12
- P2Y12, Purinergic Receptor
- P2T Purinoceptor
- Purinoceptor, P2T
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Purinergic P2Y12".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptors, G-Protein-Coupled [D12.776.543.750.695]
- Receptors, Purinergic [D12.776.543.750.695.700]
- Receptors, Purinergic P2 [D12.776.543.750.695.700.720]
- Receptors, Purinergic P2Y [D12.776.543.750.695.700.720.500]
- Receptors, Purinergic P2Y12 [D12.776.543.750.695.700.720.500.300]
- Receptors, Neurotransmitter [D12.776.543.750.720]
- Receptors, Purinergic [D12.776.543.750.720.700]
- Receptors, Purinergic P2 [D12.776.543.750.720.700.720]
- Receptors, Purinergic P2Y [D12.776.543.750.720.700.720.750]
- Receptors, Purinergic P2Y12 [D12.776.543.750.720.700.720.750.300]
Below are MeSH descriptors whose meaning is more specific than "Receptors, Purinergic P2Y12".
This graph shows the total number of publications written about "Receptors, Purinergic P2Y12" by people in this website by year, and whether "Receptors, Purinergic P2Y12" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 0 | 1 | 1 |
| 2009 | 0 | 2 | 2 |
| 2010 | 0 | 3 | 3 |
| 2012 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptors, Purinergic P2Y12" by people in Profiles.
-
Modern antiplatelet agents in coronary artery disease. Expert Rev Cardiovasc Ther. 2012 Oct; 10(10):1261-72.
-
A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial. Circ Cardiovasc Interv. 2012 Jun; 5(3):336-46.
-
Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (INNOVATE-PCI) trial. Circ Cardiovasc Interv. 2012 Jun; 5(3):347-56.
-
Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2010 Sep 14; 122(11):1056-67.
-
Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI). Am Heart J. 2010 Jul; 160(1):65-72.
-
Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet. 2010 Jan 23; 375(9711):283-93.
-
Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of platelet thromboSis with intravenous Elinogrel before PCI to optimize reperfusion in acute Myocardial Infarction (ERASE MI) pilot trial. Am Heart J. 2009 Dec; 158(6):998-1004.e1.
-
A new generation of antiplatelet agents. Curr Opin Cardiol. 2009 Jul; 24(4):307-12.
-
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol. 2007 Nov 06; 50(19):1844-51.